Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and...
Read More
For many laboratories, CFTR testing is not an occasional add-on. It is part of a routine,...
Read More